Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Besses

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
British Journal of Haematology|May 26, 2017
Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemiaAlberto Alvarez-Larrán, Alicia Senín, Concepción Fernández-Rodríguez, et al.
Blood|August 18, 2012
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneAnna L Godfrey, Edwin Chen, Francesca Pagano, et al.
The Lancet. Haematology|January 27, 2020
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 studyJean-Jacques Kiladjian, Pierre Zachee, Masayuki Hino, et al.
Blood|September 30, 2025
Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40William J Tapper, Ahmed A Z Dawoud, Joannah Score, et al.
Haematologica|April 23, 2016
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trialSrdan Verstovsek, Alessandro M Vannucchi, Martin Griesshammer, et al.
Blood|February 21, 2014
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patientsHolly L Geyer, Robyn M Scherber, Amylou C Dueck, et al.
Haematologica|May 14, 2016
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutationAlberto Alvarez-Larrán, Arturo Pereira, Paola Guglielmelli, et al.
Journal of Clinical Pathology|June 24, 2018
Essential thrombocythaemia with mutation in <i>MPL</i>: clinicopathological correlation and comparison with <i>JAK</i>2V617F-mutated and <i>CALR-</i>mutated genotypesAlberto Alvarez-Larran, Daniel Martínez, Leonor Arenillas, et al.
Haematologica|April 26, 2012
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosisJulien Broseus, Lourdes Florensa, Esther Zipperer, et al.
Haematologica|October 1, 2016
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyureaAlberto Alvarez-Larrán, Manuel Pérez-Encinas, Francisca Ferrer-Marín, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|May 26, 2017
Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemiaAlberto Alvarez-Larrán, Alicia Senín, Concepción Fernández-Rodríguez, et al.
Blood|August 18, 2012
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneAnna L Godfrey, Edwin Chen, Francesca Pagano, et al.
The Lancet. Haematology|January 27, 2020
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 studyJean-Jacques Kiladjian, Pierre Zachee, Masayuki Hino, et al.
Blood|September 30, 2025
Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40William J Tapper, Ahmed A Z Dawoud, Joannah Score, et al.
Haematologica|April 23, 2016
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trialSrdan Verstovsek, Alessandro M Vannucchi, Martin Griesshammer, et al.
Blood|February 21, 2014
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patientsHolly L Geyer, Robyn M Scherber, Amylou C Dueck, et al.
Haematologica|May 14, 2016
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutationAlberto Alvarez-Larrán, Arturo Pereira, Paola Guglielmelli, et al.
Journal of Clinical Pathology|June 24, 2018
Essential thrombocythaemia with mutation in <i>MPL</i>: clinicopathological correlation and comparison with <i>JAK</i>2V617F-mutated and <i>CALR-</i>mutated genotypesAlberto Alvarez-Larran, Daniel Martínez, Leonor Arenillas, et al.
Haematologica|April 26, 2012
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosisJulien Broseus, Lourdes Florensa, Esther Zipperer, et al.
Haematologica|October 1, 2016
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyureaAlberto Alvarez-Larrán, Manuel Pérez-Encinas, Francisca Ferrer-Marín, et al.
Pageof 5